Abstract
The price control legislations are the main policy tool used in India to make medicines accessible. It is important to understand the real impact of these interventionist policies on patients’ lives. The objective of the article is centred on understanding the effectiveness of price interventionist policy to reduce the out-of-pocket expenditure of patients. The article examines whether the ability to pay by patients is considered or linked while fixing the prices after regulation. The article focuses on the direct price control and trade margin rationalization imposed on drugs to increase accessibility. The article deliberates the drugs under both price regulations to check how significant are the price reduction and how it would reduce the inequity among the patients.
Get full access to this article
View all access options for this article.